Journals / Türk Nöroşirürji Dergsi / 2019 / Cilt: 29 - Sayı: 3

Molecular and Genetic Changes in Gliomas

Gliomalardaki Moleküler ve Genetik Değişiklikler

Pages
226–233
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, the correlation of molecular genetic markers with gliomas and new approaches to this field is discussed with a recent literature review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Molecular and genetic research in Neuro-oncology has provided new perspectives on the oncogenesis and progression of central nervous system tumors.
📊
Key Findings & Data:The World Health Organization (WHO) classification for central nervous system tumors was changed in 2016 to develop an integrated, multi-layer diagnostic model and to integrate molecular markers into the classical histopathological features.
💡
Conclusion & Impact:In this paper, the correlation of molecular genetic markers with gliomas and new approaches to this field is discussed with a recent literature review.
🔬Design:Review & Systematic Survey
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Molecular and genetic research in Neuro-oncology has provided new perspectives on the oncogenesis and progression of central nervous system tumors. The World Health Organization (WHO) classification for central nervous system tumors was changed in 2016 to develop an integrated, multi-layer diagnostic model and to integrate molecular markers into the classical histopathological features. These molecular markers have helped classify glioma cases and determine the response to the treatment as well as paving the way for individual treatments. Having parallel, fast, and reliable tests with multiple indicator focuses available at an acceptable cost is desirable. In this paper, the correlation of molecular genetic markers with gliomas and new approaches to this field is discussed with a recent literature review.

Özet

Nöro-onkoloji alanındaki moleküler ve genetik çalışmalar onkogenez ve tümörlerin progresyonu ile ilgili yeni bakış açılarınınkazanılmasını sağlamıştır. Dünya Sağlık Örgütü (WHO) santral sinir sistemi tümörlerine yönelik sınıflandırmayı 2016 yılında değiştirerekentegre, çok-katmanlı bir tanı modeli önermiş ve klasik histopatolojik niteliklere moleküler belirteçleri entegre etmiştir. Böylecesöz konusu diagnostik, prognostik ve prediktif moleküler belirteçler glioma sınıflaması ve tedavi yanıtının belirlenmesinin yanındabireysel tedavilerin de önünü açmıştır. Çoklu belirtece yönelik paralel, hızlı ve sağlıklı testlerin kabul edilebilir bir maliyetle pratikkullanıma sunulmasına ihtiyaç vardır. Yazıda moleküler genetik belirteç-glioma ilişkileri ve bu alana yönelik yeni yaklaşımlar güncelliteratür ışığında özet halinde derlenmiştir.

🔖

Cite This Article

UĞUR, H. Ç., BAYATLI, E. (2022). Molecular and Genetic Changes in Gliomas. Türk Nöroşirürji Dergsi, Cilt: 29 - Sayı: 3, 226–233. https://ajindex.com/articles/637285

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A: Glioblastoma: Pathology, molecular mechanisms and markers. Acta Neuropathol 129:829-848, 2015 2. Beier D, Schulz JB, Beier CP: Chemoresistance of glioblastoma cancer stem cells–much more complex than expected. Mol Cancer 10:128, 2011 3. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW: Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-1455, 2011 4. Bush NAO, Butowski N: The effect of molecular diagnostics on the treatment of glioma. Curr Oncol Rep 19:26, 2017 5. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038–2045, 2007 6. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 31:337-343, 2013 7. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O’Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S,